Monte Rosa Therapeutics, Inc. Common Stock GLUE
i
Market dataready · fetched 2026-11-06T20:51:44.399Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T20:51:39.465300815Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-06T20:51:43.796743+00:00
Monte Rosa Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 8.86 | 86.6% | 17.8% | |||
| 25Δ | 9.26 | 83.6% | 14.6% | |||
| 30Δ | 9.66 | 80.6% | 11.3% | |||
| 35Δ | 10.08 | 79.4% | 8.5% | |||
| 40Δ | 10.59 | 88.4% | 7.8% | |||
| 45Δ | 11.11 | 97.3% | 7.2% | |||
| 50Δ | 10.91 | 110.2% | 12.0% | 11.63 | 106.3% | 6.6% |
| 55Δ | 10.58 | 108.5% | 9.7% | 12.15 | 115.3% | 5.9% |
| 60Δ | 10.24 | 106.8% | 7.5% | 12.66 | 124.3% | 5.3% |
| 65Δ | 13.18 | 133.3% | 4.6% | |||
| 70Δ | 13.70 | 142.2% | 4.0% | |||
| 75Δ | 14.22 | 151.2% | 3.4% | |||
| 80Δ | 14.73 | 160.2% | 2.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.86
- IV
- 86.6%
- B/E move
- 17.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.26
- IV
- 83.6%
- B/E move
- 14.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.66
- IV
- 80.6%
- B/E move
- 11.3%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.08
- IV
- 79.4%
- B/E move
- 8.5%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.59
- IV
- 88.4%
- B/E move
- 7.8%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 11.11
- IV
- 97.3%
- B/E move
- 7.2%
50Δ
- Pseudo strike
- 10.91
- IV
- 110.2%
- B/E move
- 12.0%
- Pseudo strike
- 11.63
- IV
- 106.3%
- B/E move
- 6.6%
55Δ
- Pseudo strike
- 10.58
- IV
- 108.5%
- B/E move
- 9.7%
- Pseudo strike
- 12.15
- IV
- 115.3%
- B/E move
- 5.9%
60Δ
- Pseudo strike
- 10.24
- IV
- 106.8%
- B/E move
- 7.5%
- Pseudo strike
- 12.66
- IV
- 124.3%
- B/E move
- 5.3%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.18
- IV
- 133.3%
- B/E move
- 4.6%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.70
- IV
- 142.2%
- B/E move
- 4.0%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.22
- IV
- 151.2%
- B/E move
- 3.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 14.73
- IV
- 160.2%
- B/E move
- 2.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 172.23% | |
| 145.41% | |
| 185.46% | |
| 153.56% | |
| 221.37% | |
| 233.76% | |
| 144.75% | |
| 118.76% | |
| 123.09% | |
| 114.19% | |
| 120.49% | |
| 126.59% | |
| 126.34% | |
| 124.16% | |
| 127.06% | |
| 124.65% | |
| 126.10% | |
| 135.42% | |
| 140.30% | |
| 175.00% | |
| 159.74% | |
| 229.31% | |
| 226.51% | |
| 136.89% | |
| 137.38% | |
| 136.93% | |
| 148.62% | |
| 129.11% | |
| 124.21% | |
| 133.13% | |
| 131.79% | |
| 135.31% | |
| 236.43% | |
| 221.83% | |
| 167.72% | |
| 145.01% | |
| 125.45% | |
| 148.76% | |
| 154.06% | |
| 161.18% | |
| 158.06% | |
| 164.10% |
Biotechnology
GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive…
More →GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet…
More →GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company is headquartered in…
More →GYRE
Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. Leveraging its proprietary…
More →HALO
Description unavailable
More →